OPRX vs. WLDN, SOHU, ZH, IBEX, MPLN, MXCT, GRVY, OOMA, NRC, and EGHT
Should you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include Willdan Group (WLDN), Sohu.com (SOHU), Zhihu (ZH), IBEX (IBEX), MultiPlan (MPLN), MaxCyte (MXCT), Gravity (GRVY), Ooma (OOMA), National Research (NRC), and 8X8 (EGHT). These companies are all part of the "business services" industry.
OptimizeRx vs.
Willdan Group (NASDAQ:WLDN) and OptimizeRx (NASDAQ:OPRX) are both small-cap business services companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.
Willdan Group has a net margin of 3.97% compared to OptimizeRx's net margin of -27.41%. Willdan Group's return on equity of 13.84% beat OptimizeRx's return on equity.
72.3% of Willdan Group shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 9.8% of Willdan Group shares are owned by company insiders. Comparatively, 6.1% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Willdan Group had 3 more articles in the media than OptimizeRx. MarketBeat recorded 3 mentions for Willdan Group and 0 mentions for OptimizeRx. Willdan Group's average media sentiment score of 1.70 beat OptimizeRx's score of 0.00 indicating that Willdan Group is being referred to more favorably in the media.
Willdan Group received 123 more outperform votes than OptimizeRx when rated by MarketBeat users. Likewise, 66.51% of users gave Willdan Group an outperform vote while only 63.79% of users gave OptimizeRx an outperform vote.
Willdan Group presently has a consensus target price of $49.00, suggesting a potential upside of 52.13%. OptimizeRx has a consensus target price of $9.06, suggesting a potential upside of 56.79%. Given OptimizeRx's higher possible upside, analysts clearly believe OptimizeRx is more favorable than Willdan Group.
Willdan Group has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Willdan Group, indicating that it is currently the more affordable of the two stocks.
Willdan Group has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Summary
Willdan Group beats OptimizeRx on 13 of the 18 factors compared between the two stocks.
Get OptimizeRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptimizeRx Competitors List
Related Companies and Tools
This page (NASDAQ:OPRX) was last updated on 2/22/2025 by MarketBeat.com Staff
